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Introduction: Autologous fat grafting is commonly used to correct soft-tissue contour deformities. However, results
are impaired by a variable and unpredictable resorption rate. Autologous adipose-derived stromal cells in combination
with lipoinjection (cell-assisted lipotransfer) seem to favor a long-term persistence of fat grafts, thus fostering the
development of devices to be used in the operating room at the point of care, to isolate the stromal vascular fraction
(SVF) and produce SVF-enhanced fat grafts with safe and standardized protocols. Focusing on patients undergoing
breast reconstruction by lipostructure, we analyzed a standard technique, a modification of the Coleman’s procedure,
and three different commercially available devices (Lipokit, Cytori, Fastem), in terms of 1) ability to enrich fat grafts in
stem cells and 2) clinical outcome at 6 and 12 months.
Methods: To evaluate the ability to enrich stem cells, we compared, for each patient (n = 20), the standard lipoaspirate
with the respective stem cell-enriched one, analyzing yield, immunophenotype and colony-forming capacity of the SVF
cells as well as immunophenotype, clonogenicity and multipotency of the obtained adipose stem cells (ASCs). Regarding
the clinical outcome, we compared, by ultrasonography imaging, changes at 6 and 12 months in the subcutaneous
thickness of patients treated with stem-cell enriched (n = 14) and standard lipoaspirates (n = 16).
Results: Both methods relying on the enzymatic isolation of primitive cells led to significant increase in the frequency, in
the fat grafts, of SVF cells as well as of clonogenic and multipotent ASCs, while the enrichment was less prominent
for the device based on the mechanical isolation of the SVF. From a clinical point of view, patients treated with
SVF-enhanced fat grafts demonstrated, at six months, a significant superior gain of thickness of both the central and
superior-medial quadrants with respect to patients treated with standard lipotransfer. In the median-median quadrant the
effect was still persistent at 12 months, confirming an advantage of lipotransfer technique in enriching improving
long-term fat grafts.
Conclusions: This comparative study, based on reproducible biological and clinical parameters and endpoints, showed
an advantage of lipotransfer technique in enriching fat grafts in stem cells and in favoring, clinically, long-term fat grafts.* Correspondence: daniela.cesselli@uniud.it
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Fat grafting is a widely used technique that has been devel-
oped by plastic reconstructive and aesthetic surgeons [1,2].
Adipose tissue has been used for many years as autologous
filler in breast augmentation, hemifacial atrophy, facial re-
juvenation and rhinoplasty [3]. However, the potential re-
generative effect of fat grafting has been hypothesized and,
to some extent, experimented only in recent years, as in
the treatment of tissues damaged by radiotherapy [4]. The
employment of adipose tissue, both as autologous filler
and as a source of adipose stem cells (ASCs), has intro-
duced the concept of regenerative therapy into plastic re-
constructive surgery, thus leading to the publication of a
large body of literature that supports the regenerative
properties of the fat grafting techniques. ASCs are indeed
mesenchymal stem cells characterized by the ability to dif-
ferentiate, at least in vitro, into multiple cell types of all
three germ layers, including adipocytes, smooth muscle
cells, endothelial cells, neurons and hepatocytes [5-11].
Despite the reported promising results, however, lipo-
filling is burdened by variable and unpredictable graft-
take rates in the postoperative period, with reported
absorption rates varying from 20 to 90% [12].
The variability in fat graft survival has been attributed to
several causes, such as the local angiogenesis, the donor
site, sampling and processing techniques, and the type of
receiving area and its characteristics. Summarizing, three
main theories have been reported that try to explain the
evolution of the grafted adipose tissue: Neuhof in 1923 ad-
vanced the host-replacement theory [13]; Peer in 1956 out-
lined the importance of adipose cell survival [14]; and
Yoshimura and colleagues in 2009 demonstrated the pri-
mary role played by ASCs on the rate of fat engraftment
[15]. According to this latter theory, after the lipofilling pro-
cedure, almost all of the injected cells die within a few
months and are replaced by differentiation of the me-
senchymal stem cells contained in the stromal vascular
fraction (SVF) [16], the portion of the adipose tissue par-
ticularly enriched in ASCs [11].
For this reason, it has been proposed that the enrich-
ment of adipose tissue with ASCs could contribute to a
de novo formation of adipocytes and blood vessels, thus
promoting long-term volume retention of the autologous
fat graft. Consequently, a new approach named cell-
assisted lipotransfer (CAL) has been introduced [17].
CAL consists of freshly isolating SVF cells from one-half
of the aspirated fat and recombining the isolated cells
with the other half, thus using, for reconstructive pur-
poses, autologous primitive cells in combination with
lipoinjection. This process allows converting relatively
ASC-poor aspirated fat to ASC-rich fat [17].
Consistently, in the last years, numerous devices
intended for clinical use have been developed and com-
mercialized. These devices are aimed at increasing theconcentration of primitive cells in the fat graft, by auto-
mating and standardizing the procedures for extracting,
washing and concentrating the SVF from the autologous
adipose tissue, thus ensuring safety and reproducibility
of the procedures [3,15,18-23].
Although some of these clinical devices, often relying
on different principles, have been described in a number
of scientific reports specifically focused on the effective-
ness and safety of the new proposed technologies, very
few papers have directly compared these different proce-
dures in terms of SVF and ASC enrichment as well as
clinical results [18,24]. In fact, if the long-term volume
retention of the autologous fat graft is guaranteed by the
presence of ASCs, it has to be demonstrated that these
cells are more abundant in the enriched-adipose tissues
and that they are able to persistently proliferate and dif-
ferentiate into adipocytes and vessels.
In this study we analyzed four different lipotransfer tech-
niques used for breast reconstruction: the gold-standard
technique used in our department, which is a modified Cole-
man’s procedure, and three different devices available on the
market – the Cytori Celution System (Cytori Ltd., Deeside,
UK), the Lipokit Medikhan System (Medikan International
Inc, Pusan, Korea) and the Fastem Corios (CORIOS Soc.
Coop, San Giuliano Milanese (MI), Italy). Specifically, we fo-
cused our attention on the ASCs isolated from the different
products, studying stem cell yield, proliferation and differen-
tiation ability. This paper has: optimized an in vitro protocol
to compare, for each patient, standard fat grafts and stem
cell-enriched fat grafts, in terms of SVF cells and ASCs; dem-
onstrated the effectiveness of the enzymatic stem cell enrich-
ment procedures in enriching fat grafts in primitive cells;
and presented preliminary clinical data showing that the use
of adipose tissue enriched in stem cells seems to correlate
with a better persistence of the fat graft at 6 and 12 months.
Materials and methods
The independent ethics committee of the Azienda Ospe-
daliero – Universitaria of Udine approved the research
(Parere N. 103/2011/Sper). Written informed consent
was obtained from patients and all clinical investiga-
tions have been conducted according to the principles
expressed in the Declaration of Helsinki.
Tissue donors
We enrolled in the study 36 patients who underwent mam-
mary reconstruction by different lipostructure techniques
from January 2010 to January 2012. Four skilled senior plas-
tic surgeons, who belong to our department, performed the
surgical procedures following a standardized procedural
protocol.
Table 1 summarizes the clinical features of the enrolled
patients. Specifically, 16 patients underwent lipostructure
with the standard technique, a Coleman’s modified procedure
Table 1 Patients included in the study
Standard
lipoaspirate
ASC-enriched
lipoaspirate
Statistical
significance
ASC-enriched lipoaspirate
technique
Cytori Lipokit Fastem
Clinical features
n (%) 16 (44.4%) 20 (55%) 9 (25%) 5 (13.8%) 6 (16.7%)
Age (years) 49.5 (21 to 71) 48 (19 to 74) P = 0.8370 46 (41 to 70) 52 (41 to 57) 52 (19 to 74)
BMI (kg/m2) 22.35 (19.36 to
30.3)
21.4 (19.8 to
32.8)
P = 0.7520 21.30 (20.58 to
30.5)
22.19 (20 to
32.8)
21.20 (19.8 to
24.4)
Co-morbidities 0 (0.0%) 2 (10.0%) P = 0.4921 1 (11.1%) 1 (20.0%) 0 (0.0%)
Previous surgical procedure
Mastectomy 14 (87.50%) 16 (80.00%) P = 0.6722 8 (89%) 5 (100%) 3 (50%)
Quadrantectomy 1 (6.25%) 2 (10.00%) P = 1.0000 1 (11.1%) 0 (0.00%) 1 (16.7%)
None (congenital malformation) 1 (6.25%) 2 (10.00%) P = 1.0000 0 (0.00%) 0 (0.00%) 2 (33.3%)
Donor area
Abdomen 5 (31.25%) 1 (5.00%) P = 0.0689 0 (0.00%) 0 (0.00%) 1 (16.7%)
Hips 7 (43.75%) 7 (35.00%) chi-q =
0.5926
3 (22.2%) 3 (60%) 1 (16.7%)
Trochanteric region 2 (12.50%) 2 (10.00%) P = 1.0000 1 (11.1%) 0 (0.00%) 1 (16.7%)
Abdomen and hips 2 (12.50%) 4 (20%) P = 0.6722 1 (11.1%) 2 (40%) 1 (16.7%)
Hips and trochanteric region 0 (0.00%) 4 (20%) P = 0.1131 3 (22.2%) 0 (0.00%) 1 (16.7%)
Abdomen and trochanteric region 0 (0.00%) 1 (5.00%) P = 1.0000 0 (0.00%) 0 (0.00%) 1 (16.7%)
Abdomen. hips and trochanteric
region 0 (0.00%) 1 (5.00%) P = 1.0000 1 (11.1%) 0 (0.00%) 0 (0.00%)
Amount of solution infiltrated (cm3) 95 (54 to 160) 143 (60 to 230) P = 0.0540 158 (75 to 230) 145 (60 to 175) 85 (75 to 165)
Adjuvant therapies
None 6 (37.5%) 11 (55%) P = 0.3351 5 (55.6%) 2 (40%) 4 (66.7%)
RT 1 (6.25%) 3 (15.00%) P = 0.6129 1 (11.1%) 1 (20%) 1 (16.7%)
CT 7 (43.75%) 3 (15.00%) P = 0.0732 1 (11.1%) 2 (40%) 0 (0.00%)
RT and CT 2 (12.50%) 3 (15.00%) P = 1.0000 2 (22.2%) 0 (0.00%) 1 (16.7%)
Hormonal therapies 7 (43.75%) 12 (60.00%) chi-q =
0.3318
6 (67%) 4 (80%) 2 (33.3%)
Data presented as median (range) or n (%). ASC, adipose stem cell; BMI, body mass index; CT, chemotherapy; Cytori, Cytori Celution System (Cytori Ltd., Deeside,
UK) [25]; Fastem, Fastem Corios (CORIOS Soc. Coop, San Giuliano Milanese (MI), Italy); Lipokit, Lipokit Medikhan System (Medikan International Inc, Pusan, Korea)
[26]; RT, radiotherapy.
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tructure was obtained using autologous adipose tissue
enriched in SVF through three different devices: the
Cytori Celution System (Cytori [25], n = 9), the Lipokit
Medikhan System (Lipokit [26], n = 5) and the Fastem
Corios (Fastem, n = 6), following the manufacturers’ in-
struction. Briefly, in the standard procedure the breast
reconstruction was performed using directly the centri-
fuged lipoaspirate. In the other cases, one-half of the
lipoaspirates was employed to enzymatically (Cytori
and Lipokit) or mechanically (Fastem) isolate the SVF
cells and these were then added to the other half of the
lipoaspirate. Lipostructure was then performed using
the SVF-enriched lipoaspirate. A detailed description of
the techniques is presented in Additional file 1.Stem cell isolation and culture
SVFs were isolated from aliquots of the lipoaspirates used
for breast reconstruction. In the case of patients undergo-
ing reconstruction with stem cell-enriched samples, stem
cell isolation was performed from aliquots of either non-
enriched adipose tissue samples (that is, collected before
stem cell enrichment procedures) or stem cell-enriched
adipose tissue samples.
Lipoaspirates were enzymatically dissociated using a
0.025% collagenase II solution for 30 minutes at 37°C
(Worthington, Lakewood, NJ, USA) and, after neut-
ralization of the enzyme, were centrifuged at 600 × g for
10 minutes and filtered (Merck Millipore, Darmstadt,
Germany). To determine the cell yield after isolation,
cells less than 70 μm in diameter were counted and
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lipoaspirate.
To isolate and culture ASCs, we applied, with minor
modifications, a protocol optimized for culturing multi-
potent adult stem cells from normal human tissues
[5-7,9,27,28] and neoplastic human tissues [29,30]. Briefly,
freshly isolated SVF cells (1.5 × 106) were plated onto hu-
man fibronectin-coated (Sigma-Aldrich, St. Louis, MO,
USA) 100 mm dishes (Corning BV Life Sciences, Corning,
NY, USA) in a proliferation medium composed as follows:
60% low glucose Dulbecco’s modified Eagle’s medium
(Invitrogen Life Technologies, Carlsbad, CA, USA), 40%
MCDB-201, 1 mg/ml linoleic acid–bovine serum albumin,
10−9 M dexamethasone, 10−4 M ascorbic acid-2 phosphate,
1× insulin–transferrin–sodium selenite (all from Sigma-
Aldrich), 2% fetal bovine serum (StemCell Technologies,
Grenoble, France), 10 ng/ml human platelet-derived
growth factor-BB, 10 ng/ml human epidermal growth fac-
tor (both from Peprotech EC, London, UK) [5-7,9,27,28].
Medium was replaced with fresh medium every 4 days.
Once cells reached 70 to 80% confluence, they were de-
tached by TrypLE Express (Invitrogen) and replated at a
density of 1 × 103/cm2 to 2 × 103/cm2.
Cell culture assays
Colony-forming efficiency, cell growth kinetics, single-
cell cloning and multilineage differentiation were per-
formed as descried previously [6,7,9,27].
Colony-forming units of SVF cells were determined by
seeding freshly isolated cells at a concentration of 1,500
cells/cm2 in 96-well plates and counting the number of
formed colonies under a phase contrast microscope 7 days
after incubation at 37°C. Colony-forming units were ex-
amined in triplicate and by two independent investigators.
The cell population doubling time was calculated by plat-
ing ASCs in the third passage at a density of 2 × 103 cells/
cm2 in expansion medium. Medium was replaced with
fresh medium every 4 days and, at different time points (1,
2, 3, 5 and 7 days), cells were detached with TrypLE Ex-
press (Invitrogen) and counted. The population doubling
time was calculated during the log phase of growth.
To generate single cell-derived clones, a cell sorter
(MoFlo; Beckman Coulter s.r.l., Milan, Italy) was used to
automatically deposit individual ASCs onto fibronectin-
coated wells of 96-well Terasaki plates (n = 300 wells/cell
line). The cells were cultured in expansion medium with
10% fetal bovine serum. To determine the sorting effi-
ciency and to verify whether any well was properly
seeded, we utilized Vybrant CFDA SE as a cell tracker
(Molecular Probes, Invitrogen). Wells were examined
once a week. When clones reached confluence, cells
were detached utilizing TrypLE (Invitrogen) and plated
at the density of 1.5 × 103cells/cm2 on new fibronectin-
coated dishes and cultured in expansion medium.ASCs were differentiated and analyzed as described pre-
viously [6,7,9,27]. Hepatocytic differentiation was induced
by growing cells for 2 weeks at high density (2 × 104/cm2)
onto fibronectin-coated coverslips in a medium containing
0.5% fetal bovine serum (Sigma-Aldrich), 10 ng/ml fibro-
blast growth factor-4 and 20 ng/ml hepatocyte growth fac-
tor (both from Peprotech EC). Muscle cell and endothelial
cell differentiation was achieved by plating 0.5 × 104/cm2
to 1 × 104/cm2 cells in expansion medium containing 5%
fetal bovine serum (Sigma-Aldrich), 10 ng/ml basic fibro-
blast growth factor, 10 ng/ml vascular endothelial growth
factor and 10 ng/ml insulin-like growth factor-1 (all from
Peprotech EC), but not epidermal growth factor. Adi-
pogenic differentiation was induced using culture me-
dium supplemented with 0.5 mM isobutylmethylxanthine,
50 μM indomethacin and 0.5 μM dexamethasone. Cells
were allowed to become confluent and cultured for up to
2 weeks with medium exchanges every 4 days.
Flow cytometry
Freshly isolated cells or ASCs at the third passage in culture
were detached by Tryple Express and were incubated with
the properly conjugated antibodies CD10, CD13, CD29,
CD34, CD44, CD45, CD49a, CD49b, CD49d, CD59 (BD Bio-
sciences, Milan, Italy), CD66e (AbD Serotec, Kidlington, UK),
CD73, CD90 (BD Biosciences), CD105 (Serotec), CD117 (BD
Biosciences), CD133 (Miltenyi Biotec, Bergisch Gladbach,
Germany), CD271 (R&D Systems, Minneapolis, MN, USA),
HLA-DR (BD Biosciences), KDR and ABCG-2 (R&D Sys-
tem). Properly conjugated isotype-matched antibodies were
used as a negative control. The analysis was performed either
by FACS-Calibur or by FACSCanto (BD Bioscience)
[6,7,9,27]. Erythrocytes, in freshly isolated samples, were lysed
by incubating cells for 5 minutes in fluorescence-activated cell
sorting lysing solution (BD Bioscience).
Immunofluorescence and cytochemistry
Cell staining and image acquisition were conducted as de-
scribed previously [27,28] to detect Oct-4 (1:150; Abcam,
Cambridge, UK), Sox-2 (1:150; Chemicon International
Inc., Billerica, MA, USA), Nanog (1:150; Abcam), Nestin
(1:100; Millipore), vimentin (1:100; Dako, Glostrup,
Denmark), peroxisome proliferator-activated receptor
gamma (1:100; Santa Cruz Biotechnology. Inc., Heidelberg,
Germany), CD31 (1:50; Dako), smooth muscle actin (1:50;
Dako), alpha sarcomeric actin (1:100; Sigma) and c-Kit
(1:30; Dako). The accumulation of lipid droplets indicating
adipogenic differentiation was detected staining the cells
in a solution of 0.5% Oil Red-O (Sigma-Aldrich).
Clinical follow-up
To compare the clinical results of the different lipostruc-
ture techniques used in the mammary reconstruction,
ultrasound measurement of the subcutaneous thickness
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operatively as well as 6 and 12 months postoperatively.
Moreover, representative preoperative and postoperative
photographs of the mammary region, taken according to
standard projections, have been acquired. Ultrasound
measurements (7.5/13.5 MHz) have been collected with
the GE Vivide portable ultrasound Doppler (GE Health-
care, Milan, Italy). In order to standardize the procedure,
the breast mound has been divided into nine quadrants
and, although measurements were performed on all the
quadrants, comparisons between groups were performed
on the superior-medial quadrant (SMQ) and on the
median-median quadrant (MMQ; that is, the central
quadrant in the breast mound). In fact, as reported in
the literature [31], both the SMQ and the MMQ repre-
sent an area of weakness and thinness in the recon-
structed breast after mastectomy. The investigated area
corresponds to the treated area in the patients who
underwent quadrantectomy reconstructions and con-
genital malformation treatment.
Depending on the observational nature of the study
and the impossibility for some patients to undergo pre-
operative or postoperative ultrasound, some data regard-
ing presurgery or postsurgery quadrant subcutaneous
thicknesses were incomplete. Thickness gain data were
thus not available for seven patients. Analyses were per-
formed without imputing for missing data.
Statistical analysis
For the ASC study, characteristics of the population have
been described using the mean ± standard deviation or me-
dian and range for continuous variables and percentages
for categorical variables. Data were tested for normal distri-
bution using the Kolmogorov–Smirnov test. Paired t test or
Mann–Whitney test, as appropriate, was used to compare
continuous variables between two groups. Repeated-
measurements one-way analysis of variance followed by the
Bonferroni post test or the Kruskal–Wallis test followed by
Dunn’s test were used, as appropriate, to compare more
than two groups. P <0.05 was considered significant (Prism,
version 4.0c; GraphPad Software, Inc., La Jolla, CA USA).
For the clinical study, patient characteristics were de-
scribed using the median and range for continuous vari-
ables, and frequencies and percentages for categorical
variables. A t test or Wilcoxon–Mann–Whitney test was
used to compare continuous variables between standard
treatment and stem cell-enriched treatment, in accordance
with Shapiro–Wilk’s normality test results. The chi-square
test or Fisher exact test was used to compare categorical
variables, as appropriate. For detailed comparisons
among the standard group and the three enrichment
methods, the Kruskall–Wallis test was performed
because of the small sample sizes. Preoperative and
long-term data were tested with the Wilcoxon signedrank-sum test, while the Friedman test were used to
compare three groups of data.
Analyses were performed without imputing for missing
data. The total number of subjects analyzed is reported.
Results
Patients enrolled in the study
As summarized in Table 1, most of the patients enrolled
in the study underwent breast reconstruction after mast-
ectomy (n = 30), while a minority of them was treated
after a quadrantectomy (n = 3) or for a congenital malfor-
mation (Poland syndrome, n = 3). Patients treated with the
standard method did not differ significantly from those
treated with the stem cell-enriched procedure in terms of
age, body mass index, co-morbidities and therapies.
Lipoaspirates were obtained in most cases from the
hip area, followed by the abdominal and the trochanteric
regions, without significant differences between patients
treated either with the standard or ASC enrichment
procedure.
Isolation of adipose tissue stem cells from lipoaspirates
obtained by different procedures
To establish whether the enrichment procedures could
interfere with the ability to isolate primitive cells from
lipoaspirates, we analyzed 40 lipoaspirates obtained from
20 patients that underwent a CAL procedure. Specific-
ally, for each patient we compared the characteristics of
freshly isolated cells both from the non-enriched sam-
ples (n = 20) and the stem cell-enriched samples (n = 20).
We observed that, at the end of the enzymatic dissoci-
ation followed by the filtration step, both the Cytori and
Lipokit procedures determined a significant increase in
the number of recovered cells, when compared with the
respective non-enriched lipoaspirates. This was not the
case for the Fastem procedure (Figure 1A).
To establish whether the enrichment procedure modified
the composition of the isolated cells, we performed a
fluorescence-activated cell sorting analysis to determine, in
the erythrocyte-lysed samples, the fraction of CD45+
hematopoietic cells and, among the CD45-negative cells, the
expression of the mesenchymal stem cell markers CD73
and CD90 and of the endothelial marker CD31. Moreover,
we evaluated the CD34+CD45−CD31− stromal cell popula-
tion [32]. The Cytori and, especially, Fastem procedures
significantly increased the fraction of CD45-positive
hematopoietic cells, while the CD34+CD45−CD31− stromal
cell population was significantly increased by both the
Lipokit and Cytori enrichment procedures (Figure 1B). No
main differences were detected in the frequency of CD31-
positive, CD73-positive or CD90-positive cells.
When dissociated cells were cultured to obtain ASCs,
only a minority of the seeded cells was able to adhere and
proliferate (Figure 1C). Specifically, the colony-forming
Figure 1 Isolation of primitive cells from lipoaspirates and lipoaspirates enriched with stem cells. Histograms represent (A) cell yield, (B)
cell composition and (C) number of colony-forming units at 7 days from seeding. (D, E, F, G) Expression of stem cell markers in primary culture.
Proliferating cells expressed high levels of Nanog (green fluorescence, D), Sox-2 (yellow fluorescence, E) and Oct-4 (magenta fluorescence, F),
while a fraction of cells expressed c-Kit (red fluorescence, G). Nuclei are depicted by the blue fluorescence of 4′,6-diamidino-2-phenylindole. In the
histograms, results are expressed as mean ± standard deviation. For each isolation method, *P <0.05 vs. lipoaspirates. Cytori, Cytori Celution
System (Cytori Ltd., Deeside, UK) [25]; Fastem, Fastem Corios (CORIOS Soc. Coop, San Giuliano Milanese (MI), Italy); L, lipoaspirates; L + SC, stem
cell-enriched lipoaspirates; Lipokit, Lipokit Medikhan System (Medikan International Inc, Pusan, Korea) [26].
Domenis et al. Stem Cell Research & Therapy 2015, 6:2 Page 6 of 15
http://stemcellres.com/content/6/1/2efficiency, an assay often used to quantify the presence of
mesenchymal stem cells [33], was significantly increased
in samples enriched by the two enzymatic methods, Cytori
and Lipokit, but not by the mechanic Fastem method
(Figure 1C).
Despite the stringent culture conditions, proliferating
cell lines were obtained from every sample 5 to 7 days
after the primary culture confirming the high efficiency
of the optimized method [5-7,9,27].
As soon as 1 week after seeding, proliferating cells
were positive for the expression of the pluripotent state-
specific transcription factors Oct-4, Nanog and Sox-2
(Figure 1D,E,F), thus excluding that the acquisition of
these features could be related to an extensive culture
manipulation. The expression of c-Kit, the stem cell
antigen receptor, was detected in about 10% of thepopulation without significant differences between the
samples (Figure 1G).
Altogether, these results indicate that samples obtained
by the Cytori and Lipokit stem cell enrichment proce-
dures are characterized, with respect to the non-
enriched counterpart, by increased cell yield and number
of colony-forming cells. Conversely, the Fastem proced-
ure seems not to affect these parameters.
Cytori and Lipokit enrichment in stem cells persists with
passages in culture
To test the hypothesis that the persistence of ASCs in
the donated fat is required for the long-term volume re-
tention of the autologous fat graft, we verified whether
the enrichment in primitive cells persisted after exten-
sive expansion in culture. For this purpose, ASCs
Figure 2 Stem cell marker expression by adipose stem cells. Stem cells isolated from lipoaspirates (L) (A, D, G) and from lipoaspirates enriched
with stem cells (L + SC) (B, E, H) express Oct-4 (green fluorescence, A, B, C), Nanog (magenta fluorescence, D, E, F) and c-Kit (red fluorescence, G, H, I).
Nuclei are depicted by the blue fluorescence of 4′,6-diamidino-2-phenylindole. (J) Representative surface immunophenotype of adipose stem cells: histogram
overlay shows isotype control IgG staining profile (red histograms) versus specific antibody staining profile (green histograms). (K) Population doubling time.
(C, F, I, K) Results expressed as mean± standard deviation. *P <0.05 vs. L. Cytori, Cytori Celution System (Cytori Ltd., Deeside, UK) [25]; Fastem, Fastem Corios
(CORIOS Soc. Coop, San Giuliano Milanese (MI), Italy); Lipokit, Lipokit Medikhan System (Medikan International Inc, Pusan, Korea) [26].
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Figure 3 Clonogenicity of adipose stem cells. (A) Phase contrast image of a representative single-cell derived clone. (B) Quantitative evaluation of the
clonogenicity of stem cells isolated from lipoaspirates (L) and from lipoaspirates enriched with stem cells (L + SC). Data expressed as mean ± standard
deviation. *P <0.05 vs. L. (C, D, E, F) Clones are characterized by a primitive phenotype: highly expressing Oct-4 (red fluorescence, C), Nanog (green
fluorescence, D), Sox-2 (yellow fluorescence, E), c-Kit (red fluorescence, F), and the intermediate filaments nestin (green fluorescence, G) and vimentin (red
fluorescence, H). Cytori, Cytori Celution System (Cytori Ltd., Deeside, UK) [25]; Fastem, Fastem Corios (CORIOS Soc. Coop, San Giuliano Milanese (MI), Italy);
Lipokit, Lipokit Medikhan System (Medikan International Inc, Pusan, Korea) [26].
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techniques were compared with those isolated from their
nonstem cell-enriched counterparts.
As shown in Figure 2, proliferating cells at the third pas-
sage in culture (that is, ≈24th population doubling) con-
tinued to express Oct-4 and Nanog (Figure 2A,B,C,D,E,F),
transcription factors considered crucial, together with Klf-
4 and c-Myc, for the maintenance of a primitive state [34].
However, only Cytori enriched samples were character-
ized, with respect to the non-enriched counterpart, by a
significant increase in the expression of both Oct-4 and
Nanog (Figure 2C,F). Furthermore, 20 to 30% of cultured
cells derived from samples enriched in stem cells by either
Lipokit or Cytori expressed the stem cell marker c-Kit, al-
though only the latter group significantly differed from
the non-enriched counterpart (Figure 2G,H,I).
The flow cytometric analysis of the cell surface immu-
nophenotype (Figure 2J) demonstrated that every cell
line exhibited, independently of the enrichment proced-
ure, a similar mesenchymal phenotype, characterized by
the expression of CD44, CD73, CD90 and CD105 in the
absence of hematopoietic markers, such as CD45. With
the exception of c-Kit, which was more expressed both
in Cytori and Lipokit enriched samples, no other major
differences were detected (Additional file 2).
When analyzed in terms of growth kinetic, only cell
lines obtained from samples enriched in stem cells byLipokit showed a significantly reduced population doub-
ling time, while for Cytori enriched and Fastem enriched
samples the trend in increasing the growth speed did
not reach a statistical significance (Figure 2K).
Finally, to test whether enrichment procedures af-
fected clonogenicity, a crucial in vitro property of stem
cells, we performed a single cell-cloning assay compar-
ing non-enriched and stem cell-enriched paired samples
(Figure 3). Although it was possible to isolate highly pro-
liferating clones from all cell lines (Figure 3A,B), the fre-
quency of these clones was significantly increased in
Cytori and Lipokit enriched ASCs (Figure 3B). Specific-
ally, ASCs enriched by Lipokit were 2.8 (±0.6) times
more clonogenic than the non-enriched counterpart,
while Cytori enrichment determined a 2.5 (±2.1)-fold in-
crease in the frequency of clonogenic cells. Enrichment
by Fastem did not increase the clonal ability of isolated
cells. Importantly, clonal cells maintained a stable undif-
ferentiated phenotype characterized by the expression of
pluripotent state-specific transcription factors vimentin,
nestin and c-Kit (Figure 3C,D,E,F,G,H).
Adipose stem cells from Lipokit and Cytori enriched fat
grafts display superior differentiation potential in vitro
It has been hypothesized that the enrichment of adipose
tissue with stem cells could stimulate the formation of
new blood vessels and maintain the thickness of the
Figure 4 Multipotency of adipose stem cells. Stem cells isolated from lipoaspirates (L) (A, D, F, I, L) and from lipoaspirates enriched with stem cells (L +
SC) (B, E, G, J, M) were evaluated for their ability to differentiate into adipocyte-like cells staining positive for Oil-red O (red vacuoles, A, B) and peroxisome
proliferator-activated receptor gamma (magenta, D, E), endothelial-like cells positive for CD31 (green fluorescence, F, G), and muscle cells positive for smooth
muscle actin (SMA; red fluorescence, I, J) and alpha sarcometic actin (ASA; red fluorescence, L,M). Nuclei are depicted by the blue staining of either
hematoxylin or 4′,6-diamidino-2-phenylindole. (C, H, K, N) Results expressed as mean± standard deviation. *P <0.05 vs. L. Cytori, Cytori Celution System (Cytori
Ltd., Deeside, UK) [25]; Fastem, Fastem Corios (CORIOS Soc. Coop, San Giuliano Milanese (MI), Italy); Lipokit, Lipokit Medikhan System (Medikan International Inc,
Pusan, Korea) [26].
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Figure 5 Clinical evaluation. (A, B, C, D) Patient treated with a stem cell-enriched fat grafting technique. (A) Preoperative pictures of the patient
after mastectomy and immediate expander reconstruction of the left breast. (B) Ultrasound evaluation image of the preoperative subcutaneous
thickness of the mastectomy skin flap over the implant, detected at the level of the median-median quadrant (MMQ). (C) Postoperative pictures
at 6 months after the patient underwent expander substitution with an implant and contemporary fat grafting with 230 cm3 stem cell-enriched
adipose tissue (Cytori). Shape, volume, and projection of the final implant are good to excellent. (D) Ultrasound evaluation image of the subcutaneous
thickness of the mastectomy skin flap at 6 months, detected in the area of the MMQ. (E, F, G, H) Patient treated with the standard fat grafting technique.
(E) Preoperative pictures of a patient after mastectomy and immediate expander reconstruction of the right breast. (F) Ultrasound evaluation image of the
subcutaneous thickness of the mastectomy skin flap over the implant in the preoperative period, detected at the level of the MMQ. (G) Postoperative
pictures at 6 months. Reconstruction was performed with expander substitution with an implant and contemporary fat grafting with 110 cm3 adipose
tissue (standard technique). The symmetry is reached, although in the lateral view there is a lack in the right breast projection. (H) Ultrasound evaluation
image of the subcutaneous thickness of the mastectomy skin flap at 6 months, detected in the area of the MMQ. (I, J, K, L) Graph boxes showing the
subcutaneous thickness gain (mm) in the superior-median quadrant (SMQ) (I, J) and in the MMQ (K, L) at 6 months. (M, N) Graph boxes showing the
subcutaneous thickness loss (mm) in the MMQ between 6 and 12 months. Cytori, Cytori Celution System (Cytori Ltd., Deeside, UK) [25]; Fastem, Fastem
Corios (CORIOS Soc. Coop, San Giuliano Milanese (MI), Italy); Lipokit, Lipokit Medikhan System (Medikan International Inc, Pusan, Korea) [26].
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cedure could increase the frequency, within grafted sam-
ples, of multipotent cells able to originate new vessels
and adipose tissue, we exposed ASCs to adipogenic-
inducing, myogenic-inducing and endothelial-inducing
conditions (Figure 4). Cells cultured in adipocyte differ-
entiation medium accumulated Oil Red-O-positive lipid
droplets in their cytoplasm (Figure 4A,B,C) and in-
creased the expression of peroxisome proliferator-
activated receptor gamma (Figure 4D,E). Again, cell lines
obtained from Lipokit and Cytori enriched samples dis-
played a significantly increased ability to differentiate
into adipocyte-like cells.
Concerning the ability to differentiate into CD31-positive
endothelial cells, every tested cell line was able to acquire
endothelial cell features (Figure 4F,G,H). However, only
Cytori enrichment significantly improved the endothelial
differentiation capacity of ASCs (Figure 4H). Similarly, only
cell lines obtained from samples enriched by Cytori were
characterized by an increased ability to differentiate into
both smooth muscle cells (Figure 4I,J,K) and skeletal
muscle cells (Figure 4L,M,N). ASCs obtained from Lipokit
enriched samples displayed only a trend towards the im-
provement in their differentiation ability, while ASCs ob-
tained from Fastem enriched samples did not differ from
those obtained from the non-enriched counterparts.
Altogether, the accumulated evidence showed that cell
lines obtained from Cytori enriched samples were char-
acterized by an increased ability to differentiate into
endothelial-like, myocyte-like and adipocyte-like cells.
Adipose tissue grafts enriched by stem cells improve
subcutaneous thickness gain
To establish whether the use of stem cell-enriched lipoas-
pirates for breast cancer reconstruction can determine,
with respect to the standard procedure, an improvement
in the clinical outcome (Figure 5A,C,E,G), we compared
the preoperative and postoperative subcutaneous thick-
ness of the breast area by ultrasound measurements(Figure 5B,D,F,H), allowing us to compute the gain in sub-
cutaneous tissue 6 months after surgery (Figure 5I,J,K,L).
Importantly, the biological properties of the lipoaspirate
products that were employed for the standard procedure
did not differ from the above-described, nonstem cell-
enriched samples (Additional files 2 and 3).
Compared with the standard technique, stem cell enrich-
ment led to better results in terms of thickness gain in both
the SMQ (+0 mm (−11.2 mm to +4.5 mm) in the standard
treatment group vs. +3.1 mm (−4.7 mm to +8.5 mm) in the
stem cell-enriched group, P = 0.002; Figure 5I) and in the
MMQ (+0.5 mm (−16.6 mm to +6.3 mm) in the standard
treatment group vs. +4.5 mm (−0.20 mm to +8.2 mm) in
the stem cell-enriched group, P = 0.028; Figure 5K). When
considering the single technique’s performance, a difference
in thickness gain was observed for SMQ (P = 0.026;
Figure 5J) but not for MMQ (P = 0.117; Figure 5L); however,
subgroup analysis did not identify differences between the
techniques, most probably because of small sample sizes.
Finally, to evaluate the stability of fat grafts at 1 year, we
evaluated the thickness loss between 6 and 12 months in
the patients treated with stem cell-enriched lipoaspirates
and standard lipoaspirates, respectively. Again, compared
with the standard technique, stem cell enrichment led to a
significant reduction in thickness loss in the MMQ
(Figure 5M), while in the SQM the difference did not
reach statistical significance (data not shown). When
considering the single technique’s performance, a differ-
ence in thickness gain was observed for MMQ (P = 0.026;
Figure 5N), and the subgroup analysis identified the sig-
nificant superiority of Cytori.
Discussion
Adipose tissue has been used for a century as autologous
filler. After the first attempts, explored by Neuber and
Czerny at the end of the 19th century [1,2,34], lipofilling
techniques have undergone a huge development in the
1990s thanks to Coleman’s work, rapidly gaining wide-
spread diffusion [35,36].
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properties of the adipose tissue, an easily accessible
source that can be collected by procedures that are rela-
tively simple, safe and repeatable with minimal morbid-
ity. Moreover, since the adipose tissue is available in the
majority of the patients, it allows autologous approaches
devoid of immunogenic drawbacks. The main disadvan-
tage of lipofilling remains the unpredictable fat graft’s re-
sorption rate that may vary between 20 and 90% [12,37].
Since the demonstration that adipose tissue is an
abundant and accessible source of multipotent stem cells
[11], the concept of stem cell-enhanced fat grafting has
been formulated [17]. Briefly, the hypothesis is that the
supplementation of fat grafts with cells obtained from
the SVF, a cell population known to be enriched in ASCs
[32], would improve graft stability, taking advantage of
the capacity of ASC to reduce apoptosis, contribute to
vessel formation and maintain a self-renewing reservoir
of cells able to give rise to all the mature cell types con-
stituting the adipose tissue [18,38,39]. In this regard, the
first clinical studies of the Yoshimura group – showing
the ability of the so-called CAL to improve the results of
the lipostructure technique, leading to a more predict-
able and stable result [17,39,40] – were further con-
firmed by other groups both at clinical level [23,41,42]
and preclinical level [38,43-45]. Led by the accumulation
of data documenting safety and efficacy of CAL ap-
proaches, different automated, semiautomated and man-
ual devices to be used in the operating room at the
point of care have been developed to isolate with safe
and standardized protocols the SVF and to produce
SVF-enhanced fat grafts [18,21,39,46-50]. However, it is
difficult for the clinician to choose among the available
devices, since very few comparative studies have been
performed that have taken into account systematically
both biological and clinical criteria. In fact, it would be
advisable to have standards based on reproducible pa-
rameters and endpoints that could allow comparing dif-
ferent techniques [32,51].
In this paper, we compared a standard lipotransfer
technique, based on Coleman’s procedure, with three
commercially available cell lipotransfer techniques. Two
of the devices, Cytori [18,22] and Lipokit [18,49], are
closed systems allowing an enzymatic separation of the
SVF cells, while the third, Fastem, is a closed system of
filtering bags that mechanically isolates the SVF.
The comparison took into consideration both biological
and clinical criteria. Regarding the first evaluation, we
compared, for each patient, standard lipoaspirates with
the respective stem cell-enriched ones in terms of yield,
immunophenotype and colony-forming capacity of the
SVF cells as well as immunophenotype, clonogenicity and
multipotency of the culture-expanded ASCs [32]. Regard-
ing the clinical criteria, we compared, in terms ofsubcutaneous thickness gain as detected by ultrasound
imaging, the group of patients treated with stem cell-
enriched lipoaspirates with a group of patients treated
with the standard procedure.
Considering the cell yield, a higher number of cells
could be isolated from lipoaspirates enriched by both of
the enzymatic methods. Regarding the characterization of
the isolated cells, Cytori and, especially, Fastem signifi-
cantly enriched the lipoaspirate product in hematopoietic
cells, while the CD34+CD31−CD45− putative stromal cell-
containing population [32] was higher in both Lipokit and
Cytori enriched samples. A recent report by Yoshimura’s
group trying to define the cellular events guiding the graft
take in a murine model showed that CD34+ cells were
proliferating in the first 2 to 4 weeks after grafting [52],
while a xenograft transplantation study by Rubin’s group
suggested that the concentration of CD34+ progenitor
cells within the SVF could be used to predict the human
fat graft retention [45].
Accordingly, Cytori and Lipokit enriched lipoaspirates
were also characterized by an increased number of
colony-forming unit cells. The colony-forming unit
assay, commonly used to assess the frequency of pro-
genitor cells [32], supported an increased number of
primitive cells in Cytori and Lipokit enriched products.
The trend was evident also for the Fastem procedure, al-
though it did not reach statistical significance.
We further analyzed the stem cell-enriched lipoaspirates
isolating, culturing and characterizing ASCs. Many works
have been conducted showing that stem cell enrichment
devices, such as Cytori, are able to isolate ASCs, thus
allowing the surgeon to perform a CAL [18,21,22]. Add-
itionally, recent work by Dominici’s group has demon-
strated, in a rabbit subcutaneous adipose tissue autologous
regeneration model, the capacity of ASCs to reduce cell
apoptosis favoring a long-term graft performance [38].
More importantly, a randomized placebo-controlled trial
has demonstrated that enrichment of autologous fat grafts
with ex vivo expanded ASCs significantly improved graft
survival [37].
In our study, ASCs could be isolated both from non-
enriched and stem cell-enriched samples. However, dif-
ferences could be detected in ASC phenotype and func-
tion at the third passage in culture. Specifically, a larger
fraction of ASC obtained from Lipokit and Cytori
enriched lipoaspirates expressed stem cell markers such
as Nanog, Sox-2 and c-Kit, although differences reached
statistical significance only for Cytori. Similarly, ASCs
from the stem cell-enriched lipoaspirates tended to grow
faster. Regarding clonogenicity, Lipokit and Cytori de-
rived ASCs were characterized by a double number of
cells able to grow when seeded as single cells. Similarly,
ASCs obtained from the samples enriched by Lipokit
and Cytori were characterized, with respect to those
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nificantly increased ability to differentiate into adipo-
cytes (Lipokit and Cytori), endothelial cells (Cytori) and
muscle cells (Cytori). Conversely, the mechanic Fastem
enrichment procedure seemed not to significantly enrich
the samples in clonogenic and multipotent ASCs.
Altogether, the cytological criteria analyzed in this paper
seem to indicate a clear ability of the enzymatic-based
method to enrich the samples in both vascular stromal cells
and ASCs. In a recent study, Aronowitz and Ellenhorn com-
pared four different commercial cell separation systems –
Cytori, Lipokit, PNC’s Multi Station (PNC. International,
Gyeonggi- do, Republic of Korea) and CHA Biotech Cha-
Station (CHA Biotech, Kangnamgu, Republic of Korea) –
evaluating the cell yield, frequency of CD34+CD31−CD45−
and endothelial cells as well as colony-forming units of the
isolated cells, showing a clear superiority for the Cytori sys-
tem [18]. However, the residual enzyme levels observed with
Lipokit was 57-fold higher than that observed with Cytori,
and this can explain why in our work, in which we used not
the SVF but the lipoaspirate enriched in the isolated cells,
we did not observe such a clear difference between Cytori
and Lipokit. In fact, addition of the isolated cells to the
lipoaspirates could have neutralized the residual enzymatic
activity, possibly reducing the negative effect of the enzymes
on the isolated cells. This suggests the importance of the
standardization of the sample to be used to define the prop-
erties of the donated fat graft. In Aronowitz and Ellenhorn’s
work, moreover, the authors did not study ASCs and a clin-
ical evaluation is missing.
Regarding the clinical results, in this pilot study we used
an ultrasound evaluation of the subcutaneous thickness of
the breast area corresponding to the SMQ and MMQ.
The clinical evaluation of the results is a key point to es-
tablish the entity of the graft take and, ultimately, the ef-
fectiveness of the technique. In this regard, the magnetic
resonance imaging and three-dimensional surface imaging
are considered ideal examinations to quantify the entity of
the graft takes. In fact, both techniques are non-invasive
tools characterized by high accuracy and reproducibility in
evaluating the effective volume persistence [53]. However,
these methods are cost-effective, and, in the case of the
three-dimensional surface imaging, no information on the
breast tissue is available. To ensure the possibility to have
easy, fast and low-cost measurements, we have employed
an ultrasound device [54,55]. The ultrasonographic ana-
lysis gives the possibility to extend the analysis to several
patients and even to increase the frequency of the exami-
nations, thus improving the evaluation of the fat graft per-
sistence/resorption kinetic. In this paper we have shown
that, 6 months after fat grafting, patients treated with stem
cell-enriched lipoaspirates showed, with respect to those
treated with the standard procedure, a significant superior
gain in the subcutaneous thickness of both MMQ andSMQ; moreover, the significant superior thickness loss be-
tween 6 and 12 months in the MMQ of patients treated
with standard lipoaspirates confirmed a better stability
over time of fat grafts obtained with stem cell-enriched
procedures.
The millimeter size of the thickness analyzed has made
ultrasound imaging a proper, easy, and low-cost tech-
nique to be used for the measurements. Moreover, to
overcome the subjective nature of ultrasound measure-
ments, a dedicated team has been selected to control the
patients and a standardization of the data collection pro-
cedure through a nine-quadrant breast pattern has been
implemented.
Our results are in line with all reports indicating the
clinical advantage of using the CAL procedure over a
standard lipotransfer [17,23,39-42,44].
Recently, Peltoniemi and colleagues raised doubts re-
garding the advantage of using stem cell enrichment in
cosmetic fat transplantation to the breast [56]. Speci-
fically, for breast augmentation they used either li-
poaspirates obtained by water-assisted lipotransfer or
water-assisted lipotransfer lipoaspirate enriched with
stromal stem cells obtained using the Cytori system. The
water-assisted lipotransfer method is based on the use of
the Bodyjet System (Body-Jet; Human Med, Eclipse Ltd.,
Dallas, Texas), which allows a gentle liposuction through
the aid of a water jet pulse dissecting the adipocytes
from the subcutaneous tissue; its effectiveness, in terms
of both fat graft survival rate and overall clinical out-
come, has been reported by different groups [57,58].
However, in Peltoniemi and colleagues’ work, no differ-
ences in the ASC phenotype was seen between the two
lipoaspirates, thus suggesting that a more specific study
on ASC presence and function in the two lipoaspirates
would add crucial information.
Considering instead the three different devices, despite
the fact that, accordingly with in vitro data, Cytori-
treated patients displayed a trend to a better clinical out-
come, no significant differences between the different
CAL procedures could be detected, perhaps because of
the small number of analyzed patients.
In fact, the major weakness points of this study are rep-
resented by the sample size of enrolled patients and by the
short-term follow-up (12 months). A larger case study and
a longer follow-up period are needed to confirm the re-
sults, and a double-blind ultrasound measurement study
is needed to assess the accuracy and reproducibility of our
standardized protocol. Moreover, a cost analysis on a large
population would clarify whether CAL represents a real
advantage. In fact, lipostructure techniques are widespread
and usually patients must be subjected to repeated inter-
ventions to achieve the optimum result. The use of stem
cells should increase the long-term graft performance, re-
ducing the number of the surgical procedures required to
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should therefore take into account the costs related to the
CAL procedures and the savings due to the reduction in
the number of surgeries required.
Conclusions
In this paper, applying our in vitro protocol to isolate,
quantify and characterize SVF cells and ASCs from fat
grafts, we have demonstrated a significant superiority of
the enzymatic stem cell enrichment procedures over the
standard procedure. Accordingly, our in vivo protocol,
based on the ultrasonographic assessment of the subcuta-
neous thickness of the breast area, confirmed the clinical
advantage of CAL techniques in reducing the graft resorp-
tion at 1 year, especially in the central part of the breast.
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